

Peter A Mccullough

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2872733/publications.pdf>

Version: 2024-02-01

421
papers

28,559
citations

9254

74
h-index

6128

159
g-index

430
all docs

430
docs citations

430
times ranked

25273
citing authors

#	ARTICLE	IF	CITATIONS
1	Kidney Disease as a Risk Factor for Development of Cardiovascular Disease. <i>Circulation</i> , 2003, 108, 2154-2169.	1.6	3,082
2	Rapid Measurement of B-Type Natriuretic Peptide in the Emergency Diagnosis of Heart Failure. <i>New England Journal of Medicine</i> , 2002, 347, 161-167.	13.9	3,057
3	Acute Renal Failure After Coronary Intervention. <i>American Journal of Medicine</i> , 1997, 103, 368-375.	0.6	1,553
4	Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. <i>Critical Care</i> , 2013, 17, R25.	2.5	969
5	Contrast-Induced Acute Kidney Injury. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1419-1428.	1.2	802
6	The Central Role of Endothelial Dysfunction in Cardiorenal Syndrome. <i>CardioRenal Medicine</i> , 2017, 7, 104-117.	0.7	800
7	Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. <i>European Heart Journal</i> , 2010, 31, 703-711.	1.0	797
8	Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2019, 139, e840-e878.	1.6	619
9	Contrast-Induced Acute Kidney Injury. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1465-1473.	1.2	533
10	Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. <i>Journal of the American College of Cardiology</i> , 2002, 39, 60-69.	1.2	468
11	Epidemiology and Prognostic Implications of Contrast-Induced Nephropathy. <i>American Journal of Cardiology</i> , 2006, 98, 5-13.	0.7	354
12	Risk Prediction of Contrast-Induced Nephropathy. <i>American Journal of Cardiology</i> , 2006, 98, 27-36.	0.7	354
13	Cardiorenal Syndrome Type 1. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1031-1042.	1.2	332
14	BNP Consensus Panel 2004: A Clinical Approach for the Diagnostic, Prognostic, Screening, Treatment Monitoring, and Therapeutic Roles of Natriuretic Peptides in Cardiovascular Diseases. <i>Congestive Heart Failure</i> , 2004, 10, 1-30.	2.0	285
15	Derivation and validation of cutoffs for clinical use of cell cycle arrest biomarkers. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 2054-2061.	0.4	232
16	Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 1304-1317.	2.6	232
17	Prevalence of CKD and Comorbid Illness in Elderly Patients in the United States: Results From the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2010, 55, S23-S33.	2.1	230
18	Diagnosis of Acute Kidney Injury Using Functional and Injury Biomarkers: Workgroup Statements from the Tenth Acute Dialysis Quality Initiative Consensus Conference. <i>Contributions To Nephrology</i> , 2013, 182, 13-29.	1.1	205

#	ARTICLE	IF	CITATIONS
19	Cardiorespiratory Fitness and Short-term Complications After Bariatric Surgery. <i>Chest</i> , 2006, 130, 517-525.	0.4	204
20	Independent Components of Chronic Kidney Disease as a Cardiovascular Risk State. <i>Archives of Internal Medicine</i> , 2007, 167, 1122.	4.3	197
21	Acute cardiac effects of marathon running. <i>Journal of Applied Physiology</i> , 2010, 108, 1148-1153.	1.2	197
22	Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. <i>American Heart Journal</i> , 2002, 144, 226-232.	1.2	195
23	Contrast-Induced Nephropathy. <i>Critical Care Clinics</i> , 2005, 21, 261-280.	1.0	167
24	Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality. <i>American Heart Journal</i> , 2008, 156, 277-283.	1.2	160
25	Accelerated Atherosclerotic Calcification and Morbidity in End-stage Renal Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 1585-1598.	2.2	160
26	National Kidney Foundation's Kidney Early Evaluation Program (KEEP) Annual Data Report 2009: Executive Summary. <i>American Journal of Kidney Diseases</i> , 2010, 55, S1-S3.	2.1	160
27	Cardio-Pulmonary-Renal Interactions. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2433-2448.	1.2	157
28	Analysis of long-term survival after revascularization in patients with chronic kidney disease presenting with acute coronary syndromes. <i>American Journal of Cardiology</i> , 2003, 92, 509-514.	0.7	156
29	Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program. <i>Kidney International</i> , 2005, 67, 1483-1488.	2.6	145
30	Current Overview on Hypercoagulability in COVID-19. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 393-403.	1.0	145
31	Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. <i>European Journal of Heart Failure</i> , 2015, 17, 1050-1056.	2.9	143
32	Uncovering Heart Failure in Patients with a History of Pulmonary Disease: Rationale for the Early Use of B-type Natriuretic Peptide in the Emergency Department. <i>Academic Emergency Medicine</i> , 2003, 10, 198-204.	0.8	142
33	B-type natriuretic peptides: a diagnostic breakthrough for clinicians. <i>Reviews in Cardiovascular Medicine</i> , 2003, 4, 72-80.	0.5	142
34	CKD and Cardiovascular Disease in Screened High-Risk Volunteer and General Populations: The Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. <i>American Journal of Kidney Diseases</i> , 2008, 51, S38-S45.	2.1	141
35	Obesity and Age of First Non-ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2008, 52, 979-985.	1.2	140
36	Risk Factors for Heart Failure in Patients With Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated With Bardoxolone Methyl. <i>Journal of Cardiac Failure</i> , 2014, 20, 953-958.	0.7	139

#	ARTICLE	IF	CITATIONS
37	Vadadustat in Patients with Anemia and Non-dialysis-Dependent CKD. <i>New England Journal of Medicine</i> , 2021, 384, 1589-1600.	13.9	137
38	Endothelial dysfunction contributes to COVID-19-associated vascular inflammation and coagulopathy. <i>Reviews in Cardiovascular Medicine</i> , 2020, 21, 315.	0.5	136
39	Determinants of Serum Creatinine Trajectory in Acute Contrast Nephropathy. <i>Journal of Interventional Cardiology</i> , 2002, 15, 349-354.	0.5	135
40	Pathophysiology of the Cardiorenal Syndromes: Executive Summary from the Eleventh Consensus Conference of the Acute Dialysis Quality Initiative (ADQI). <i>Contributions To Nephrology</i> , 2013, 182, 82-98.	1.1	135
41	Trends in the Incidence of Acute Kidney Injury in Patients Hospitalized With Acute Myocardial Infarction. <i>Archives of Internal Medicine</i> , 2012, 172, 246.	4.3	129
42	Arterial Stiffness in the Heart Disease of CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 918-928.	3.0	128
43	Mechanisms Contributing to Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated with Bardoxolone Methyl. <i>American Journal of Nephrology</i> , 2014, 39, 499-508.	1.4	124
44	Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 798-809.	2.2	124
45	Galectin-3: A Novel Blood Test for the Evaluation and Management of Patients With Heart Failure. <i>Reviews in Cardiovascular Medicine</i> , 2011, 12, 200-210.	0.5	122
46	Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study Equations: Risk Factors for and Complications of CKD and Mortality in the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2011, 57, S9-S16.	2.1	116
47	Cardiovascular disease in the kidney transplant recipient: epidemiology, diagnosis and management strategies. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 760-773.	0.4	115
48	Intensive Hemodialysis, Left Ventricular Hypertrophy, and Cardiovascular Disease. <i>American Journal of Kidney Diseases</i> , 2016, 68, S5-S14.	2.1	112
49	Design of Combination Angiotensin Receptor Blocker and Angiotensin-Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D). <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 361-368.	2.2	111
50	Cardiovascular Toxicity of Epoetin-Alfa in Patients with Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2013, 37, 549-558.	1.4	111
51	Class effects of SGLT2 inhibitors on cardiorenal outcomes. <i>Cardiovascular Diabetology</i> , 2019, 18, 99.	2.7	111
52	Impact of Chronic Kidney Disease Upon Survival Among Implantable Cardioverter-Defibrillator Recipients. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2004, 11, 199-204.	0.6	109
53	Impact of Obesity on Cardiovascular Disease. <i>Endocrinology and Metabolism Clinics of North America</i> , 2008, 37, 663-684.	1.2	108
54	Cardiorenal Syndromes: An Executive Summary from the Consensus Conference of the Acute Dialysis Quality Initiative (ADQI). <i>Contributions To Nephrology</i> , 2010, 165, 54-67.	1.1	106

#	ARTICLE	IF	CITATIONS
55	Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis. <i>New England Journal of Medicine</i> , 2021, 384, 1601-1612.	13.9	106
56	Implementation of Novel Biomarkers in the Diagnosis, Prognosis, and Management of Acute Kidney Injury: Executive Summary from the Tenth Consensus Conference of the Acute Dialysis Quality Initiative (ADQI). <i>Contributions To Nephrology</i> , 2013, 182, 5-12.	1.1	105
57	Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection. <i>American Journal of Medicine</i> , 2021, 134, 16-22.	0.6	105
58	Determinants of coronary vascular calcification in patients with chronic kidney disease and end-stage renal disease: a systematic review. <i>Journal of Nephrology</i> , 2004, 17, 205-15.	0.9	105
59	B-type natriuretic peptide and renal disease. <i>Heart Failure Reviews</i> , 2003, 8, 355-358.	1.7	102
60	Cardiovascular implications of proteinuria: an indicator of chronic kidney disease. <i>Nature Reviews Cardiology</i> , 2009, 6, 301-311.	6.1	99
61	Prevalence and Associations of Anemia of CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. <i>American Journal of Kidney Diseases</i> , 2008, 51, S46-S55.	2.1	95
62	Changes in renal markers and acute kidney injury after marathon running. <i>Nephrology</i> , 2011, 16, 194-199.	0.7	95
63	Prevention of Contrast-Induced AKI. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1618-1631.	2.2	94
64	Pathophysiology of Cardiorenal Syndrome Type 2 in Stable Chronic Heart Failure: Workgroup Statements from the Eleventh Consensus Conference of the Acute Dialysis Quality Initiative (ADQI). <i>Contributions To Nephrology</i> , 2013, 182, 117-136.	1.1	93
65	Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. <i>American Journal of Cardiology</i> , 2003, 92, 919-923.	0.7	92
66	Contrast-Induced Nephropathy (CIN) Consensus Working Panel: executive summary. <i>Reviews in Cardiovascular Medicine</i> , 2006, 7, 177-97.	0.5	92
67	Cardiorenal risk: an important clinical intersection. <i>Reviews in Cardiovascular Medicine</i> , 2002, 3, 71-6.	0.5	90
68	Pathogenesis of Cardiorenal Syndrome Type 1 in Acute Decompensated Heart Failure: Workgroup Statements from the Eleventh Consensus Conference of the Acute Dialysis Quality Initiative (ADQI). <i>Contributions To Nephrology</i> , 2013, 182, 99-116.	1.1	83
69	Potassium homeostasis in health and disease: A scientific workshop cosponsored by the National Kidney Foundation and the American Society of Hypertension. <i>Journal of the American Society of Hypertension</i> , 2017, 11, 783-800.	2.3	81
70	Characteristics and Outcomes in Patients Presenting With COVID-19 and ST-Segment Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2020, 131, 1-6.	0.7	81
71	The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis. <i>CardioRenal Medicine</i> , 2020, 10, 1-10.	0.7	80
72	Radiocontrast-Induced Acute Kidney Injury. <i>Nephron Physiology</i> , 2008, 109, p61-p72.	1.5	79

#	ARTICLE	IF	CITATIONS
73	Uncovering Heart Failure in Patients with a History of Pulmonary Disease: Rationale for the Early Use of B-type Natriuretic Peptide in the Emergency Department. <i>Academic Emergency Medicine</i> , 2003, 10, 198-204.	0.8	78
74	Current Risk of Contrast-Induced Acute Kidney Injury After Coronary Angiography and Intervention: A Reappraisal of the Literature. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1225-1228.	0.8	75
75	The Synergistic Relationship Between Estimated GFR and Microalbuminuria in Predicting Long-term Progression to ESRD or Death in Patients With Diabetes: Results From the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2013, 61, S12-S23.	2.1	72
76	Coronary Artery Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 611-616.	2.2	70
77	Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs. <i>Food and Chemical Toxicology</i> , 2022, 164, 113008.	1.8	70
78	Cardiorenal Syndrome Type 3: Pathophysiologic and Epidemiologic Considerations. <i>Contributions To Nephrology</i> , 2013, 182, 137-157.	1.1	68
79	Educational programs improve the preparation for dialysis and survival of patients with chronic kidney disease. <i>Kidney International</i> , 2014, 85, 686-692.	2.6	68
80	Delays in Presentation in Patients With Acute Myocardial Infarction During the COVID-19 Pandemic. <i>Cardiology Research</i> , 2020, 11, 386-391.	0.5	67
81	Annual Progression of Coronary Calcification in Trials of Preventive Therapies. <i>Archives of Internal Medicine</i> , 2009, 169, 2064.	4.3	66
82	Cardiovascular disease in chronic kidney disease from a cardiologist's perspective. <i>Current Opinion in Nephrology and Hypertension</i> , 2004, 13, 591-600.	1.0	65
83	Acute kidney injury with iodinated contrast. <i>Critical Care Medicine</i> , 2008, 36, S204-S211.	0.4	65
84	Proposal for a Functional Classification System of Heart Failure in Patients With End-Stage Renal Disease. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1246-1252.	1.2	64
85	Awareness and Knowledge of Clinical Practice Guidelines for CKD Among Internal Medicine Residents: A National Online Survey. <i>American Journal of Kidney Diseases</i> , 2008, 52, 1061-1069.	2.1	63
86	Intensive Hemodialysis and Treatment Complications and Tolerability. <i>American Journal of Kidney Diseases</i> , 2016, 68, S43-S50.	2.1	62
87	Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 90-99.	0.4	62
88	Cardiorespiratory Fitness and Obstructive Sleep Apnea Syndrome in Morbidly Obese Patients. <i>Chest</i> , 2008, 134, 539-545.	0.4	61
89	Bundle branch block patterns, age, renal dysfunction, and heart failure mortality. <i>International Journal of Cardiology</i> , 2005, 102, 303-308.	0.8	60
90	Gray zone BNP levels in heart failure patients in the emergency department: Results from the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT) multicenter study. <i>American Heart Journal</i> , 2006, 151, 1006-1011.	1.2	60

#	ARTICLE	IF	CITATIONS
91	Trends in Mineral Metabolism: Kidney Early Evaluation Program (KEEP) and the National Health and Nutrition Examination Survey (NHANES) 1999-2004. <i>American Journal of Kidney Diseases</i> , 2008, 51, S56-S68.	2.1	60
92	Cardiorenal Syndrome Type 4: Insights on Clinical Presentation and Pathophysiology from the Eleventh Consensus Conference of the Acute Dialysis Quality Initiative (ADQI). <i>Contributions To Nephrology</i> , 2013, 182, 158-173.	1.1	59
93	Curriculum in cardiology: Integrated diagnosis and management of diastolic heart failure. <i>American Heart Journal</i> , 2007, 153, 189-200.	1.2	58
94	Reducing Contrast-Induced Acute Kidney Injury Using a Regional Multicenter Quality Improvement Intervention. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 693-700.	0.9	58
95	Effects of Intra-Arterial and Intravenous Iso-Osmolar Contrast Medium (Iodixanol) on the Risk of Contrast-Induced Acute Kidney Injury: A Meta-Analysis. <i>CardioRenal Medicine</i> , 2011, 1, 220-234.	0.7	57
96	Arrhythmia and Sudden Death in Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 721-734.	2.2	57
97	Mortality benefit of angiotensin-converting enzyme inhibitors after cardiac events in patients with end-stage renal disease. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2002, 3, 188-191.	1.0	56
98	Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19). <i>Reviews in Cardiovascular Medicine</i> , 2020, 21, 517.	0.5	56
99	Impact of treating the metabolic syndrome on chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2009, 5, 520-528.	4.1	54
100	The Relationship Between B-type Natriuretic Peptide and Health Status in Patients With Heart Failure. <i>Journal of Cardiac Failure</i> , 2005, 11, 414-421.	0.7	53
101	Continuous versus bolus intermittent loop diuretic infusion in acutely decompensated heart failure: a prospective randomized trial. <i>Critical Care</i> , 2014, 18, R134.	2.5	53
102	Potassium Homeostasis in Health and Disease: A Scientific Workshop Cosponsored by the National Kidney Foundation and the American Society of Hypertension. <i>American Journal of Kidney Diseases</i> , 2017, 70, 844-858.	2.1	53
103	Kinetics of Urinary Cell Cycle Arrest Markers for Acute Kidney Injury Following Exposure to Potential Renal Insults. <i>Critical Care Medicine</i> , 2018, 46, 375-383.	0.4	52
104	Bioimpedance-Guided Hydration for the Prevention of Contrast-Induced Kidney Injury. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2880-2889.	1.2	52
105	Etiology and pathophysiology of new-onset heart failure: Evaluation by myocardial perfusion imaging. <i>Journal of Nuclear Cardiology</i> , 2009, 16, 82-91.	1.4	51
106	Acute and chronic cardiovascular effects of hyperkalemia: new insights into prevention and clinical management. <i>Reviews in Cardiovascular Medicine</i> , 2014, 15, 11-23.	0.5	50
107	Chronic Kidney Disease and Sudden Death: Strategies for Prevention. <i>Blood Purification</i> , 2004, 22, 136-142.	0.9	48
108	Relationship of B-type natriuretic peptide and anemia in patients with and without heart failure: A substudy from the Breathing Not Properly (BNP) Multinational Study. <i>American Journal of Hematology</i> , 2005, 80, 174-180.	2.0	48

#	ARTICLE	IF	CITATIONS
109	Prevalence of Hyperuricemia in Patients With Acute Heart Failure With Either Reduced or Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , 2017, 120, 1146-1150.	0.7	48
110	Epidemiology of contrast-induced nephropathy. <i>Reviews in Cardiovascular Medicine</i> , 2003, 4 Suppl 5, S3-9.	0.5	48
111	Kidney Early Evaluation Program: A Community-Based Screening Approach to Address Disparities in Chronic Kidney Disease. <i>Seminars in Nephrology</i> , 2010, 30, 66-73.	0.6	47
112	Phidippides Cardiomyopathy: A Review and Case Illustration. <i>Clinical Cardiology</i> , 2012, 35, 69-73.	0.7	46
113	Loop diuretics in acute heart failure: beyond the decongestive relief for the kidney. <i>Critical Care</i> , 2015, 19, 296.	2.5	44
114	CKD Awareness in the United States: The Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2008, 52, 382-383.	2.1	42
115	Heart Failure in End-Stage Kidney Disease: Pathophysiology, Diagnosis, and Therapeutic Strategies. <i>Seminars in Nephrology</i> , 2018, 38, 600-617.	0.6	42
116	Prognostic Significance of Hyperuricemia in Patients With Acute Heart Failure. <i>American Journal of Cardiology</i> , 2016, 117, 1616-1621.	0.7	41
117	ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen. <i>Current Atherosclerosis Reports</i> , 2017, 19, 62.	2.0	41
118	Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, Phase 3 study. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 137-150.	0.4	41
119	Cardiovascular Disease in Chronic Kidney Disease: Data from the Kidney Early Evaluation Program (KEEP). <i>Current Diabetes Reports</i> , 2011, 11, 47-55.	1.7	40
120	Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use. <i>American Journal of Kidney Diseases</i> , 2016, 68, S24-S32.	2.1	40
121	SARS-CoV-2 (COVID-19) and intravascular volume management strategies in the critically ill. <i>Baylor University Medical Center Proceedings</i> , 2020, 33, 370-375.	0.2	40
122	Cardiovascular damage resulting from chronic excessive endurance exercise. <i>Missouri Medicine</i> , 2012, 109, 312-21.	0.3	39
123	Cardiorenal Syndrome and the Role of the Bone-Mineral Axis and Anemia. <i>American Journal of Kidney Diseases</i> , 2015, 66, 196-205.	2.1	38
124	The deadly triangle of anemia, renal insufficiency, and cardiovascular disease: implications for prognosis and treatment. <i>Reviews in Cardiovascular Medicine</i> , 2005, 6, 1-10.	0.5	38
125	Cardiorenal Syndrome Type 5: Clinical Presentation, Pathophysiology and Management Strategies from the Eleventh Consensus Conference of the Acute Dialysis Quality Initiative (ADQI). <i>Contributions To Nephrology</i> , 2013, 182, 174-194.	1.1	37
126	Intensive Hemodialysis, Blood Pressure, and Antihypertensive Medication Use. <i>American Journal of Kidney Diseases</i> , 2016, 68, S15-S23.	2.1	37

#	ARTICLE	IF	CITATIONS
127	Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection. <i>Reviews in Cardiovascular Medicine</i> , 2020, 21, 611.	0.5	36
128	Cardiac and Renal Fibrosis in Chronic Cardiorenal Syndromes. <i>Nephron Clinical Practice</i> , 2014, 127, 106-112.	2.3	35
129	Prevalence and Prognosis of Hyperkalemia in Patients with Acute Myocardial Infarction. <i>American Journal of Medicine</i> , 2016, 129, 858-865.	0.6	35
130	Perioperative THR-184 and AKI after Cardiac Surgery. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 670-679.	3.0	35
131	Serum catalytic iron as a novel biomarker of vascular injury in acute coronary syndromes. <i>EuroIntervention</i> , 2009, 5, 336-342.	1.4	35
132	Changes in B-type natriuretic peptide levels in hemodialysis and the effect of depressed left ventricular function. <i>Advances in Chronic Kidney Disease</i> , 2005, 12, 117-124.	0.6	34
133	Pre-Procedural Bioimpedance Vectorial Analysis of Fluid Status and Prediction of Contrast-Induced Acute Kidney Injury. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1387-1394.	1.2	34
134	Vitamin D deficiency in association with endothelial dysfunction: Implications for patients with COVID-19. <i>Reviews in Cardiovascular Medicine</i> , 2020, 21, 339.	0.5	34
135	Emergency Evaluation of Chest Pain in Patients With Advanced Kidney Disease. <i>Archives of Internal Medicine</i> , 2002, 162, 2464.	4.3	33
136	Lipoic Acid in the Prevention of Acute Kidney Injury. <i>Nephron</i> , 2016, 134, 133-140.	0.9	33
137	Costs and outcomes of patients admitted with chest pain and essentially normal electrocardiograms. <i>Clinical Cardiology</i> , 1998, 21, 22-26.	0.7	32
138	Slowing the progression of diabetic nephropathy and its cardiovascular consequences. <i>American Heart Journal</i> , 2004, 148, 243-251.	1.2	32
139	Patient Discomfort Associated with the Use of Intra-arterial Iodinated Contrast Media: A Meta-Analysis of Comparative Randomized Controlled Trials. <i>BMC Medical Imaging</i> , 2011, 11, 12.	1.4	32
140	Outcomes and Prognostic Factors of Systolic as Compared With Diastolic Heart Failure in Urban America. <i>Congestive Heart Failure</i> , 2005, 11, 6-11.	2.0	31
141	Prevention of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1777-1784.	0.4	31
142	Optimal cut points of plasma and urine neutrophil gelatinase-associated lipocalin for the prediction of acute kidney injury among critically ill adults: retrospective determination and clinical validation of a prospective multicentre study. <i>BMJ Open</i> , 2017, 7, e016028.	0.8	31
143	Effects of sodium glucose co-transporter 2 inhibitors on the kidney. <i>Diabetes and Vascular Disease Research</i> , 2018, 15, 375-386.	0.9	31
144	Primer: practical approach to the selection of patients for and application of EECF. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2006, 3, 623-632.	3.3	30

#	ARTICLE	IF	CITATIONS
145	Cardiorenal Interaction: Appropriate Treatment of Cardiovascular Risk Factors to Improve Outcomes in Chronic Kidney Disease. <i>Postgraduate Medicine</i> , 2010, 122, 25-34.	0.9	30
146	Neutrophil Gelatinase-Associated Lipocalin: A Novel Marker of Contrast Nephropathy Risk. <i>American Journal of Nephrology</i> , 2012, 35, 509-514.	1.4	30
147	Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 200-205.	1.4	30
148	ABT-719 for the Prevention of Acute Kidney Injury in Patients Undergoing High-Risk Cardiac Surgery: A Randomized Phase 2b Clinical Trial. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	30
149	Amplification of Atherosclerotic Calcification and MÄ¶nckeberg's Sclerosis: A Spectrum of the Same Disease Process. <i>Advances in Chronic Kidney Disease</i> , 2008, 15, 396-412.	0.6	29
150	Dysglycemia Predicts Cardiovascular and Kidney Disease in the Kidney Early Evaluation Program. <i>Journal of Clinical Hypertension</i> , 2010, 12, 51-58.	1.0	29
151	Antecedent Administration of Angiotensin-Ä¶verting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVID-19 Syndrome. <i>Journal of the American Heart Association</i> , 2020, 9, e017364.	1.6	29
152	Anemia of cardiorenal syndrome. <i>Kidney International Supplements</i> , 2021, 11, 35-45.	4.6	29
153	Performance of Multiple Cardiac Biomarkers Measured in the Emergency Department in Patients with Chronic Kidney Disease and Chest Pain. <i>Academic Emergency Medicine</i> , 2002, 9, 1389-1396.	0.8	29
154	Diagnostic and therapeutic utility of B-type natriuretic peptide in patients with renal insufficiency and decompensated heart failure. <i>Reviews in Cardiovascular Medicine</i> , 2004, 5, 16-25.	0.5	29
155	Timing of Angiography and Revascularization in Acute Coronary Syndromes: An Analysis of the TACTICS-TIMI-18 Trial. <i>Journal of Interventional Cardiology</i> , 2004, 17, 81-86.	0.5	28
156	Effect of Lipid Modification on Progression of Coronary Calcification. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, S115-S119.	3.0	28
157	Myocardial Ischemia in Patients with Diastolic Dysfunction and Heart Failure. <i>Current Cardiology Reports</i> , 2010, 12, 216-222.	1.3	28
158	Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study Equations: Prevalence of and Risk Factors for Diabetes Mellitus in CKD in the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2011, 57, S24-S31.	2.1	28
159	Application of a Cardiac Arrest Score in Patients with Sudden Death and ST Segment Elevation for Triage to Angiography and Intervention. <i>Journal of Interventional Cardiology</i> , 2002, 15, 257-261.	0.5	27
160	Multimodality Prevention of Contrast-Induced Acute Kidney Injury. <i>American Journal of Kidney Diseases</i> , 2008, 51, 169-172.	2.1	27
161	Performance of Multiple Cardiac Biomarkers Measured in the Emergency Department in Patients with Chronic Kidney Disease and Chest Pain. <i>Academic Emergency Medicine</i> , 2002, 9, 1389-1396.	0.8	26
162	Lipoprotein-associated phospholipase A ₂ : role in atherosclerosis and utility as a cardiovascular biomarker. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 425-438.	0.6	26

#	ARTICLE	IF	CITATIONS
163	Anemia and Associated Clinical Outcomes in Patients With Heart Failure Due to Reduced Left Ventricular Systolic Function. <i>Clinical Cardiology</i> , 2013, 36, 611-620.	0.7	26
164	Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease. <i>Kidney International</i> , 2019, 96, 1030-1036.	2.6	26
165	Cardiovascular calcification in patients with chronic renal failure: Are we on target with this risk factor?. <i>Kidney International</i> , 2004, 66, S18-S24.	2.6	25
166	Sustainable Community-Based CKD Screening Methods Employed by the National Kidney Foundation's Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2011, 57, S4-S8.	2.1	25
167	Cardiorenal syndromes. <i>World Journal of Cardiology</i> , 2011, 3, 1.	0.5	25
168	A Call to Action to Develop Integrated Curricula in Cardiorenal Medicine. <i>Blood Purification</i> , 2017, 44, 251-259.	0.9	25
169	Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers and outcomes in patients with COVID-19: a systematic review and meta-analysis. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 919-930.	0.6	25
170	Serum Cystatin C, Renal Filtration Function, and Left Ventricular Remodeling. <i>Circulation: Heart Failure</i> , 2009, 2, 86-89.	1.6	24
171	Urgent need for individual mobile phone and institutional reporting of at home, hospitalized, and intensive care unit cases of SARS-CoV-2 (COVID-19) infection. <i>Reviews in Cardiovascular Medicine</i> , 2020, 21, 1.	0.5	24
172	Practical experience using galectin-3 in heart failure. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 52, 1425-31.	1.4	23
173	How Trialists and Pharmaceutical Sponsors Have Failed Us by Thinking That Acute Heart Failure Is a 48-Hour Illness. <i>American Journal of Cardiology</i> , 2017, 120, 505-508.	0.7	23
174	Benefits and Risks of Continuing Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Antagonists, and Mineralocorticoid Receptor Antagonists during Hospitalizations for Acute Heart Failure. <i>CardioRenal Medicine</i> , 2020, 10, 69-84.	0.7	23
175	Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients. <i>Future Microbiology</i> , 2022, 17, 339-350.	1.0	21
176	Review article: Risks of coronary artery calcification in chronic kidney disease: Do the same rules apply?. <i>Nephrology</i> , 2009, 14, 428-436.	0.7	20
177	Urine Catalytic Iron and Neutrophil Gelatinase-Associated Lipocalin as Companion Early Markers of Acute Kidney Injury after Cardiac Surgery: A Prospective Pilot Study. <i>CardioRenal Medicine</i> , 2013, 3, 7-16.	0.7	20
178	Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Pro. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 2079-2084.	2.2	20
179	Urinary 11-Dehydro-Thromboxane B 2 and Mortality in Patients With Stable Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2017, 119, 972-977.	0.7	20
180	Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 2039-2048.	0.4	20

#	ARTICLE	IF	CITATIONS
181	Ventricular Fibrillation Storm in Coronavirus 2019. American Journal of Cardiology, 2020, 135, 177-180.	0.7	20
182	Prediction and Prevention of Contrast Nephropathy. Journal of Interventional Cardiology, 2001, 14, 547-558.	0.5	19
183	Impact of Reduced Kidney Function on Cardiopulmonary Fitness in Patients with Systolic Heart Failure. American Journal of Nephrology, 2010, 32, 226-233.	1.4	19
184	Subclinical and clinical contrast-induced acute kidney injury: data from a novel blood marker for determining the risk of developing contrast-induced nephropathy (ENCINO), a prospective study. Renal Failure, 2015, 37, 187-191.	0.8	19
185	Major Adverse Renal and Cardiac Events After Coronary Angiography and Cardiac Surgery. Annals of Thoracic Surgery, 2018, 105, 1724-1730.	0.7	19
186	Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY) Tj ETQq0 0 0 rgBT/Overlook 10 Tf 50		
187	In-Hospital Mortality and Major Adverse Cardiovascular Events after Kidney Transplantation in the United States. CardioRenal Medicine, 2019, 9, 51-60.	0.7	19
188	Antihypertensive drugs and risk of COVID-19?. Lancet Respiratory Medicine, the, 2020, 8, e29.	5.2	19
189	Early multidrug treatment of SARS-CoV-2 infection (COVID-19) and reduced mortality among nursing home (or outpatient/ambulatory) residents. Medical Hypotheses, 2021, 153, 110622.	0.8	19
190	Influence of Chronic Renal Failure on Cardiac Structure —. Journal of the American College of Cardiology, 2016, 67, 1183-1185.	1.2	18
191	Preeclampsia as a Form of Type 5 Cardiorenal Syndrome: An Underrecognized Entity in Women's Cardiovascular Health. CardioRenal Medicine, 2018, 8, 160-172.	0.7	18
192	Mortality Risk Assessment Using CHA(2)DS(2)-VASc Scores in Patients Hospitalized With Coronavirus Disease 2019 Infection. American Journal of Cardiology, 2020, 137, 111-117.	0.7	18
193	Contrast induced acute kidney injury in interventional cardiology: an update and key guidance for clinicians. Reviews in Cardiovascular Medicine, 2020, 21, 9.	0.5	18
194	Evaluation and treatment of coronary artery disease in patients with end-stage renal disease. Kidney International, 2005, 67, S51-S58.	2.6	17
195	Darapladib and atherosclerotic plaque: Should lipoprotein-associated phospholipase A2 be a therapeutic target?. Current Atherosclerosis Reports, 2009, 11, 334-337.	2.0	17
196	Diabetic Cardiovascular Disease Predicts Chronic Kidney Disease Awareness in the Kidney Early Evaluation Program. CardioRenal Medicine, 2011, 1, 45-52.	0.7	17
197	Interpreting the Wide Range of NT-proBNP Concentrations in Clinical Decision Making. Journal of the American College of Cardiology, 2018, 71, 1201-1203.	1.2	17
198	Cardionephrology: Proposal for a Futuristic Educational Approach to a Contemporary Need. CardioRenal Medicine, 2018, 8, 296-301.	0.7	17

#	ARTICLE	IF	CITATIONS
199	Development and Initial Validation of the PROMISÂ®-Plus-HF Profile Measure. <i>Circulation: Heart Failure</i> , 2019, 12, e005751.	1.6	17
200	Coronary Calcification and Cardiac Events after Percutaneous Intervention in Dialysis Patients. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2001, 8, 133-137.	3.1	16
201	Chronic kidney disease from screening, detection, and awareness, to prevention. <i>The Lancet Global Health</i> , 2016, 4, e288-e289.	2.9	16
202	Comparative Efficacy of Transradial Versus Transfemoral Approach for Coronary Angiography and Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2016, 118, 482-488.	0.7	16
203	Clinical Impact of Changes in Hemodynamic Indices of Contractile Function During Treatment of Acute Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , 2018, 24, 43-50.	0.7	16
204	A Review of the Use of Iloprost, A Synthetic Prostacyclin, in the Prevention of Radiocontrast Nephropathy in Patients Undergoing Coronary Angiography and Intervention. <i>Clinical Cardiology</i> , 2015, 38, 492-498.	0.7	15
205	The Role of Dendritic and Endothelial Cells in Cardiorenal Syndrome. <i>CardioRenal Medicine</i> , 2018, 8, 92-104.	0.7	15
206	Utility of natriuretic peptides to assess and manage patients with heart failure receiving angiotensin receptor blocker/neprilysin inhibitor therapy. <i>Postgraduate Medicine</i> , 2018, 130, 299-307.	0.9	15
207	Impact of Durable Ventricular Assist Device Support on Outcomes of Patients with Congenital Heart Disease Waiting for Heart Transplant. <i>ASAIO Journal</i> , 2020, 66, 513-519.	0.9	15
208	Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19). <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	15
209	Fulminant Acute Kidney Injury in a Young Patient with Novel Coronavirus 2019. <i>CardioRenal Medicine</i> , 2020, 10, 217-222.	0.7	15
210	Continuation of Chronic Heart Failure Therapies During Heart Failure Hospitalization â€“ a Review. <i>Reviews in Cardiovascular Medicine</i> , 2019, 20, 111.	0.5	15
211	Sorting out the evidence on natriuretic peptides. <i>Reviews in Cardiovascular Medicine</i> , 2003, 4 Suppl 4, S13-9.	0.5	15
212	Cardiorenal Nexus: A Review With Focus on Combined Chronic Heart and Kidney Failure, and Insights From Recent Clinical Trials. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	15
213	Acute coronary syndromes in patients with renal failure. <i>Current Cardiology Reports</i> , 2003, 5, 266-270.	1.3	14
214	Resuscitation for the specialty of nephrology: is cardioneurology the answer?. <i>Kidney International</i> , 2018, 93, 25-26.	2.6	14
215	Usefulness of Oral Ferric Citrate in Patients With Iron-Deficiency Anemia and Chronic Kidney Disease With or Without Heart Failure. <i>American Journal of Cardiology</i> , 2018, 122, 683-688.	0.7	14
216	Meta-analysis of outcomes of patients with COVID-19 infection with versus without gastrointestinal symptoms. <i>Baylor University Medical Center Proceedings</i> , 2020, 33, 366-369.	0.2	14

#	ARTICLE	IF	CITATIONS
217	Six-Month Outcomes for COVID-19 Negative Patients with Acute Myocardial Infarction Before Versus During the COVID-19 Pandemic. <i>American Journal of Cardiology</i> , 2021, 147, 16-22.	0.7	14
218	Opportunities for improvement in the diagnosis and treatment of heart failure. <i>Clinical Cardiology</i> , 2003, 26, 231-237.	0.7	13
219	Impact of body mass index on outcomes of enhanced external counterpulsation therapy. <i>American Heart Journal</i> , 2006, 151, 139.e9-139.e13.	1.2	13
220	Renal Function and Scaled Troponin in Patients Presenting to the Emergency Department with Symptoms of Myocardial Infarction. <i>American Journal of Nephrology</i> , 2017, 45, 304-309.	1.4	13
221	Piecing together the evidence on anemia: the link between chronic kidney disease and cardiovascular disease. <i>Reviews in Cardiovascular Medicine</i> , 2005, 6 Suppl 3, S4-12.	0.5	13
222	Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis of Early COVID-19 and Treated at Home Within 3 Days or After 3 Days of Symptom Onset with Prescribed and Non-Prescribed Treatments Between November 2020 and August 2021. <i>Medical Science Monitor</i> , 2021, 28, e935379.	0.5	13
223	Iso-osmolar contrast media and adverse renal and cardiac events after percutaneous cardiovascular intervention. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 331-341.	0.6	12
224	Serial Urinary Tissue Inhibitor of Metalloproteinase-2 and Insulin-Like Growth Factor-Binding Protein 7 and the Prognosis for Acute Kidney Injury over the Course of Critical Illness. <i>CardioRenal Medicine</i> , 2019, 9, 358-369.	0.7	12
225	COVID-19-Associated Systemic Thromboembolism: A Case Report and Review of the Literature. <i>CardioRenal Medicine</i> , 2020, 10, 462-469.	0.7	12
226	Opportunities for improvement in the cardiovascular care of patients with end-stage renal disease. <i>Advances in Chronic Kidney Disease</i> , 2004, 11, 294-303.	0.6	11
227	Novel Markers and Therapies for Patients with Acute Heart Failure and Renal Dysfunction. <i>American Journal of Medicine</i> , 2015, 128, 312.e1-312.e22.	0.6	11
228	Contemporary practice patterns related to the risk of acute kidney injury in the catheterization laboratory: Results from a survey of Society of Cardiovascular Angiography and Intervention (SCAI) cardiologists. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 383-392.	0.7	11
229	Volume expansion and contrast-induced acute kidney injury. <i>Lancet, The</i> , 2017, 389, 1277-1278.	6.3	11
230	Plasma Volume and Renal Function Predict Six-Month Survival after Hospitalization for Acute Decompensated Heart Failure. <i>CardioRenal Medicine</i> , 2018, 8, 61-70.	0.7	11
231	Cardiovascular Risk Reduction in Patients With Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2415-2418.	1.2	11
232	Nomenclature in nephrology: preserving 'renal'™ and 'nephro' in the glossary of kidney health and disease. <i>Journal of Nephrology</i> , 2021, 34, 639-648.	0.9	11
233	Serum creatinine and cystatin C-based estimates of glomerular filtration rate are misleading in acute heart failure. <i>ESC Heart Failure</i> , 2021, 8, 3070-3081.	1.4	11
234	Comprehensive Review of the Relative Clinical Utility of B-Type Natriuretic Peptide and N-Terminal Pro-B-Type Natriuretic Peptide Assays in Cardiovascular Disease. <i>Open Heart Failure Journal</i> , 2009, 2, 6-17.	0.5	11

#	ARTICLE	IF	CITATIONS
235	Contribution of ApoCIII to Diabetic Dyslipidemia and Treatment With Volanesorsen. <i>Reviews in Cardiovascular Medicine</i> , 2018, 19, 32-37.	0.5	11
236	Predictors of 30-day re-admissions in patients with infective endocarditis: a national population based cohort study. <i>Reviews in Cardiovascular Medicine</i> , 2020, 21, 123.	0.5	11
237	Management of gastrointestinal bleeding in patients anticoagulated with dabigatran compared with warfarin: a retrospective, comparative case review. <i>Cardiovascular Diagnosis and Therapy</i> , 2014, 4, 224-31.	0.7	11
238	Effects of weight loss and pharmacotherapy on inflammatory markers of cardiovascular disease. <i>Expert Review of Cardiovascular Therapy</i> , 2005, 3, 743-759.	0.6	10
239	Renal safety of iodixanol. <i>Expert Review of Cardiovascular Therapy</i> , 2006, 4, 655-661.	0.6	10
240	Statin therapy in renal disease: Harmful or protective?. <i>Current Atherosclerosis Reports</i> , 2007, 9, 18-24.	2.0	10
241	Executive Summary: Kidney Early Evaluation Program (KEEP) 2008 Annual Data Report. <i>American Journal of Kidney Diseases</i> , 2009, 53, S1-S2.	2.1	10
242	Contrast-Induced Nephropathy. <i>Interventional Cardiology Clinics</i> , 2014, 3, 357-362.	0.2	10
243	Oxidative stress reflected by increased F2-isoprostanes is associated with increasing urinary 11-dehydro thromboxane B2 levels in patients with coronary artery disease. <i>Thrombosis Research</i> , 2016, 148, 85-88.	0.8	10
244	A Report on Myocarditis Adverse Events in the U.S. Vaccine Adverse Events Reporting System (VAERS) in Association with COVID-19 Injectable Biological Products. <i>Current Problems in Cardiology</i> , 2021, , 101011.	1.1	10
245	A Call to Action to Develop Integrated Curricula in Cardiorenal Medicine. <i>Reviews in Cardiovascular Medicine</i> , 2017, 18, 93-99.	0.5	10
246	Questionnaire instrument to assess knowledge of chronic kidney disease clinical practice guidelines among internal medicine residents. <i>Journal of Evaluation in Clinical Practice</i> , 2009, 15, 733-738.	0.9	9
247	Prevention of Cardiorenal Syndromes. <i>Contributions To Nephrology</i> , 2010, 165, 101-111.	1.1	9
248	Micronutrients and Cardiorenal Disease: Insights into Novel Assessments and Treatment. <i>Blood Purification</i> , 2011, 31, 177-185.	0.9	9
249	Diagnosis of Cardiovascular Disease in Patients with Chronic Kidney Disease. <i>Blood Purification</i> , 2012, 33, 112-118.	0.9	9
250	Dysglycemia but not lipids is associated with abnormal urinary albumin excretion in diabetic kidney disease: a report from the Kidney Early Evaluation Program (KEEP). <i>BMC Nephrology</i> , 2012, 13, 104.	0.8	9
251	Ascorbic Acid for the Prevention of Contrast-Induced Acute Kidney Injury. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2176-2177.	1.2	9
252	Real or Perceived: Hyperkalemia Is a Major Deterrent for Renin-Angiotensin Aldosterone System Inhibition in Heart Failure. <i>Nephron</i> , 2018, 138, 173-175.	0.9	9

#	ARTICLE	IF	CITATIONS
253	Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial Results. <i>American Journal of Nephrology</i> , 2020, 51, 276-288.	1.4	9
254	Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: Design and baseline characteristics. <i>American Heart Journal</i> , 2021, 235, 1-11.	1.2	9
255	Beyond serum creatinine: defining the patient with renal insufficiency and why?. <i>Reviews in Cardiovascular Medicine</i> , 2003, 4 Suppl 1, S2-6.	0.5	9
256	Rapid bedside coronary angiography with a portable fluoroscopic imaging system. , 1997, 41, 449-455.		8
257	Substantial Weight Gain During Adulthood: The Road to Bariatric Surgery. <i>Preventive Cardiology</i> , 2005, 8, 155-159.	1.1	8
258	Early Detection of Acute Kidney Injury With Neutrophil Gelatinase-Associated Lipocalin. <i>Journal of the American College of Cardiology</i> , 2011, 57, 1762-1764.	1.2	8
259	National Kidney Foundation's Kidney Early Evaluation Program (KEEP) Annual Data Report 2010: Executive Summary. <i>American Journal of Kidney Diseases</i> , 2011, 57, S1-S3.	2.1	8
260	Endothelial Cell Autoantibodies in Predicting Declining Renal Function, End-Stage Renal Disease, or Death in Adult Type 2 Diabetic Nephropathy. <i>Frontiers in Endocrinology</i> , 2014, 5, 128.	1.5	8
261	Frequency of Fluid Overload and Usefulness of Bioimpedance in Patients Requiring Intensive Care for Sepsis Syndromes. <i>Baylor University Medical Center Proceedings</i> , 2016, 29, 12-15.	0.2	8
262	Residual thromboxane activity and oxidative stress. <i>Coronary Artery Disease</i> , 2017, 28, 287-293.	0.3	8
263	Aging Male Spontaneously Hypertensive Rat as an Animal Model for the Evaluation of the Interplay between Contrast-Induced Acute Kidney Injury and Cardiorenal Syndrome in Humans. <i>CardioRenal Medicine</i> , 2017, 7, 1-10.	0.7	8
264	Usefulness of alirocumab and evolocumab for the treatment of patients with diabetic dyslipidemia. <i>Baylor University Medical Center Proceedings</i> , 2018, 31, 180-184.	0.2	8
265	The economic impact of clinically significant tricuspid regurgitation in a large, administrative claims database. <i>Journal of Medical Economics</i> , 2020, 23, 521-528.	1.0	8
266	B-Type Natriuretic Peptide and Its Clinical Implications in Heart Failure. <i>The American Heart Hospital Journal</i> , 2004, 2, 26-33.	0.2	7
267	Determinants of markedly increased B-type natriuretic peptide in patients with ST-segment elevation myocardial infarction. <i>American Journal of Emergency Medicine</i> , 2011, 29, 141-147.	0.7	7
268	A Decade After the KDOQI CKD Guidelines: Impact on the National Kidney Foundation's Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2012, 60, 692-693.	2.1	7
269	The Management of Acute Coronary Syndromes in Patients With Chronic Kidney Disease. <i>Advances in Chronic Kidney Disease</i> , 2014, 21, 472-479.	0.6	7
270	Personalized Treatment of Heart Failure with Biomarker Guidance Using a Novel Disease Severity Score. <i>Baylor University Medical Center Proceedings</i> , 2017, 30, 139-142.	0.2	7

#	ARTICLE	IF	CITATIONS
271	Cardiovascular outcomes in diabetic kidney disease: insights from recent clinical trials. <i>Kidney International Supplements</i> , 2018, 8, 8-17.	4.6	7
272	Community-Acquired Acute Kidney Injury as a Risk Factor of de novo Heart Failure Hospitalization. <i>CardioRenal Medicine</i> , 2019, 9, 252-260.	0.7	7
273	Impact of mitral regurgitation on cardiovascular hospitalization and death in newly diagnosed heart failure patients. <i>ESC Heart Failure</i> , 2020, 7, 1502-1509.	1.4	7
274	Major Adverse Renal and Cardiovascular Events following Intra-Arterial Contrast Media Administration in Hospitalized Patients with Comorbid Conditions. <i>CardioRenal Medicine</i> , 2021, 11, 193-199.	0.7	7
275	Phosphate Control: The Next Frontier in Dialysis Cardiovascular Mortality. <i>CardioRenal Medicine</i> , 2021, 11, 123-132.	0.7	7
276	Synthetic mRNAs; Their Analogue Caps and Contribution to Disease. <i>Diseases (Basel, Switzerland)</i> , 2021, 9, 57.	1.0	7
277	Alterations in Doppler-derived renal venous stasis index during recompensation of right heart failure and fluid overload in a patient with pulmonary hypertension. <i>Reviews in Cardiovascular Medicine</i> , 2019, 20, 263.	0.5	7
278	Optimal dialysis for the end-stage renal disease patient with cardiovascular disease. <i>Advances in Chronic Kidney Disease</i> , 2004, 11, 261-273.	0.6	6
279	Cardiovascular risk modification in participants with coronary disease screened by the Kidney Early Evaluation Program. <i>Internal Medicine Journal</i> , 2010, 40, 833-841.	0.5	6
280	Acute Kidney Injury After Carotid Artery Stenting. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1515-1517.	1.1	6
281	Dialysis fistulas and heart failure. <i>European Heart Journal</i> , 2017, 38, 1924-1925.	1.0	6
282	The effect of major adverse renal cardiovascular event (MARCE) incidence, procedure volume, and unit cost on the hospital savings resulting from contrast media use in inpatient angioplasty. <i>Journal of Medical Economics</i> , 2018, 21, 356-364.	1.0	6
283	Prognostic value of urinary 11-dehydrothromboxane B ₂ for mortality: A cohort study of stable coronary artery disease patients treated with aspirin. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 653-658.	0.7	6
284	Effects of Bardoxolone Methyl on Magnesium in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. <i>CardioRenal Medicine</i> , 2019, 9, 316-325.	0.7	6
285	The CatLet score: a new coronary angiographic scoring tool accommodating the variable coronary anatomy for the first time. <i>Journal of Thoracic Disease</i> , 2019, 11, 5199-5209.	0.6	6
286	SARS-CoV-2 infection and the COVID-19 pandemic: a call to action for therapy and interventions to resolve the crisis of hospitalization, death, and handle the aftermath. <i>Reviews in Cardiovascular Medicine</i> , 2021, 22, 9.	0.5	6
287	Understanding and Overcoming the Challenges Related to Cardiovascular Trials Involving Patients with Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1435-1444.	2.2	6
288	Cardioneurology from the point of view of the cardiologist: no more agree to disagree" getting to "yes" for every patient. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1995-1999.	1.4	6

#	ARTICLE	IF	CITATIONS
289	Interseção cardiorrenal: confluência para o futuro. Arquivos Brasileiros De Cardiologia, 2007, 88, 117-126.	0.3	6
290	Lipids, biomarkers, and noninvasive imaging of atherosclerotic disease activity in clinical trials. Reviews in Cardiovascular Medicine, 2008, 9, 142-9.	0.5	6
291	Percutaneous Coronary Interventions in the High-Risk Renal Patient: Strategies for Renal Protection and Vascular Protection. Cardiology Clinics, 2005, 23, 299-310.	0.9	5
292	Editorial: Contrast-Induced Acute Kidney Injury: Shifting from Elective to Urgent Coronary Intervention. Journal of Interventional Cardiology, 2010, 23, 467-469.	0.5	5
293	Chronic kidney disease as a risk factor for acute coronary syndromes in patients presenting to the emergency room with chest pain. Translational Research, 2012, 159, 391-396.	2.2	5
294	Efficacy of Subcutaneous Versus Intravenous Administration of Furosemide in Patients With Worsening Heart Failure. JACC: Heart Failure, 2018, 6, 266-267.	1.9	5
295	Detection of Atherosclerotic Cardiovascular Disease in Patients with Advanced Chronic Kidney Disease in the Cardiology and Nephrology Communities. CardioRenal Medicine, 2018, 8, 285-295.	0.7	5
296	Semaglutide and GLP-1 analogues as weight-loss agents. Lancet, The, 2018, 392, 615-616.	6.3	5
297	Identifying suspected familial chylomicronemia syndrome. Baylor University Medical Center Proceedings, 2018, 31, 284-288.	0.2	5
298	Considerations for Management of Acute Coronary Syndromes During the SARS-CoV-2 (COVID-19) Pandemic. American Journal of Cardiology, 2020, 131, 115-119.	0.7	5
299	Role of endothelial cell receptors in the context of SARS-CoV-2 infection (COVID-19). Baylor University Medical Center Proceedings, 2021, 34, 262-268.	0.2	5
300	B-Type Natriuretic Peptide: Beyond Diagnostic Applications. , 2012, , 67-77.		5
301	Clinical Utility of a Biomarker to Detect Contrast-Induced Acute Kidney Injury during Percutaneous Cardiovascular Procedures. CardioRenal Medicine, 2022, 12, 11-19.	0.7	5
302	The Current and Future Landscape of Urinary Thromboxane Testing to Evaluate Atherothrombotic Risk. Reviews in Cardiovascular Medicine, 2014, 15, 119-130.	0.5	5
303	Roles for SGLT2 Inhibitors in Cardiorenal Disease. CardioRenal Medicine, 2022, 12, 81-93.	0.7	5
304	Does quality of life evidence assist in the selection of patients for resynchronization therapy?. Journal of Interventional Cardiac Electrophysiology, 2003, 7, 71-76.	0.9	4
305	Statin therapy in renal disease: Harmful or protective?. Current Diabetes Reports, 2007, 7, 467-473.	1.7	4
306	New therapeutic agents for diabetic kidney disease. Therapy: Open Access in Clinical Medicine, 2008, 5, 553-575.	0.2	4

#	ARTICLE	IF	CITATIONS
307	Impact of Enhanced External Counterpulsation on Heart Failure Rehospitalization in Patients With Ischemic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2016, 117, 901-905.	0.7	4
308	Potassium Excretion and Outcomes in CKD: Is K Intake OK?. <i>American Journal of Kidney Diseases</i> , 2017, 69, 325-327.	2.1	4
309	First and recurrent events after percutaneous coronary intervention: implications for survival analyses. <i>Scandinavian Cardiovascular Journal</i> , 2019, 53, 299-304.	0.4	4
310	Cardiovascular disease care fragmentation in kidney transplantation: a call for action. <i>Kidney International</i> , 2019, 96, 568-571.	2.6	4
311	Acute coronary syndromes in the perioperative period after kidney transplantation in United States. <i>Clinical Transplantation</i> , 2020, 34, e14083.	0.8	4
312	Screening, detection, and management of heart failure in the SARS-CoV2 (COVID-19) pandemic. <i>Heart Failure Reviews</i> , 2021, 26, 973-979.	1.7	4
313	Comparison of Survival in Patients With Clinically Significant Tricuspid Regurgitation With and Without Heart Failure (From the Optum Integrated File). <i>American Journal of Cardiology</i> , 2021, 144, 125-130.	0.7	4
314	Measuring the Variation in the Prevention and Treatment of CI-AKI Among Interventional Cardiologists. <i>Current Problems in Cardiology</i> , 2021, 46, 100851.	1.1	4
315	Key updates in Cardio-Nephrology from 2018: Springboard to a Bright Future. <i>Reviews in Cardiovascular Medicine</i> , 2018, 19, 113-116.	0.5	4
316	Understanding and Managing Atrial Fibrillation in Patients with Kidney Disease. <i>Journal of Atrial Fibrillation</i> , 2015, 7, 1069.	0.5	4
317	Chronic angina: new medical options for treatment. <i>Reviews in Cardiovascular Medicine</i> , 2005, 6, 152-61.	0.5	4
318	Nutritional Deficiencies and Sarcopenia in Heart Failure: A Therapeutic Opportunity to Reduce Hospitalization and Death. <i>Reviews in Cardiovascular Medicine</i> , 2016, 17 Suppl 1, S30-S39.	0.5	4
319	Balancing Low-density Lipoprotein Cholesterol Reduction and Hepatotoxicity With Lomitapide Mesylate and Mipomersen in Patients With Homozygous Familial Hypercholesterolemia. <i>Reviews in Cardiovascular Medicine</i> , 2017, 18, 21-28.	0.5	4
320	Cardiovascular risk reduction and preservation of renal function in the early nephropathy patient. <i>Advances in Chronic Kidney Disease</i> , 2004, 11, 184-191.	0.6	3
321	Do implantable cardioverter-defibrillators improve survival in dialysis patients after cardiac arrest?. <i>Nature Clinical Practice Nephrology</i> , 2006, 2, 70-71.	2.0	3
322	Chronic kidney disease as a cardiovascular risk state and considerations for the use of statins. <i>Journal of Clinical Lipidology</i> , 2008, 2, 318-327.	0.6	3
323	Screening, Diagnosis, and Management of CAD in Asymptomatic Diabetic Patients —. <i>JACC: Cardiovascular Imaging</i> , 2014, 7, 1011-1012.	2.3	3
324	Cardiorenal Syndromes: Advances in Determining Diagnosis, Prognosis and Therapy. <i>Journal of Cardiovascular Diseases & Diagnosis</i> , 2015, 03, .	0.0	3

#	ARTICLE	IF	CITATIONS
325	Estimating Renal Filtration, Drug Dosing, and Clinical Outcomes. Journal of the American College of Cardiology, 2015, 65, 2724-2725.	1.2	3
326	Atrophy of the Heart After Insertion of a Left Ventricular Assist Device and Closure of the Aortic Valve. American Journal of Cardiology, 2016, 117, 878-879.	0.7	3
327	Relation Between Proprotein Convertase Subtilisin/Kexin Type 9 and Directly Measured Low-Density Lipoprotein Cholesterol. Baylor University Medical Center Proceedings, 2017, 30, 16-20.	0.2	3
328	SP421SODIUM ZIRCONIUM CYCLOSILICATE FOR HYPERKALAEMIA IN PATIENTS WITH DIABETES MELLITUS: RETROSPECTIVE ANALYSIS OF A 12 MONTH OPEN LABEL, PHASE 3 STUDY. Nephrology Dialysis Transplantation, 2018, 33, i489-i490.	0.4	3
329	FP071SAFETY AND EFFICACY OF SODIUM ZIRCONIUM CYCLOSILICATE FOR LONG-TERM TREATMENT OF HYPERKALAEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE: RESULTS FROM AN OPEN-LABEL, PHASE 3 STUDY. Nephrology Dialysis Transplantation, 2018, 33, i72-i72.	0.4	3
330	The healthcare burden of disease progression in medicare patients with functional mitral regurgitation. Journal of Medical Economics, 2019, 22, 909-916.	1.0	3
331	Treatment of Orthostatic Hypotension Due to Autonomic Dysfunction (Neurogenic Orthostatic) Tj ETQq1 1 0.784314 rgBT /Overlock Therapy, 2019, 8, 145-150.	1.1	3
332	Disconnect between community testing and hospitalization for SARS-CoV-2 (COVID-19) infection. Baylor University Medical Center Proceedings, 2020, 33, 481-481.	0.2	3
333	Ventricular Septal Myectomy for the Treatment of Left Ventricular Outflow Tract Obstruction Due to Fabry Disease. American Journal of Cardiology, 2020, 132, 160-164.	0.7	3
334	Role of Ischemic Heart Disease in Major Adverse Renal and Cardiac Events Among Individuals With Heart Failure With Preserved Ejection Fraction (from the TOPCAT Trial). American Journal of Cardiology, 2021, 142, 91-96.	0.7	3
335	Influence of myocardial ischemia on outcomes in patients with systolic versus non-systolic heart failure. American Journal of Cardiovascular Disease, 2011, 1, 167-75.	0.5	3
336	Coronary Artery Plaque and Cardiotoxicity as a Result of Extreme Endurance Exercise. Missouri Medicine, 2014, 111, 95-98.	0.3	3
337	Usefulness of Combined Renin-Angiotensin System Inhibitors and Diuretic Treatment In Patients Hospitalized with COVID-19. American Journal of Cardiology, 2022, , .	0.7	3
338	Scope of cardiovascular complications in patients with kidney disease. Ethnicity and Disease, 2002, 12, S3-44-8.	1.0	3
339	Ximelagatran: a novel oral direct thrombin inhibitor for long-term anticoagulation. Reviews in Cardiovascular Medicine, 2004, 5, 99-103.	0.5	3
340	Anemia: a modifiable risk factor for heart disease. Introduction. Reviews in Cardiovascular Medicine, 2005, 6 Suppl 3, S1-3.	0.5	3
341	The rosiglitazone meta-analysis. Reviews in Cardiovascular Medicine, 2007, 8, 123-6.	0.5	3
342	Differential diagnosis and overlap of acute chest discomfort and dyspnea in the emergency department. Reviews in Cardiovascular Medicine, 2010, 11 Suppl 2, S13-23.	0.5	3

#	ARTICLE	IF	CITATIONS
343	An evidence-based algorithm for the use of B-type natriuretic testing in acute coronary syndromes. <i>Reviews in Cardiovascular Medicine</i> , 2010, 11 Suppl 2, S51-65.	0.5	3
344	Spontaneous Coronary Artery Dissection: A Review of Pathogenesis, Presentations, Treatment, and Outcomes. <i>Reviews in Cardiovascular Medicine</i> , 2017, 18, 29-36.	0.5	3
345	Overview of B-type Natriuretic Peptide as a Blood Test. <i>Congestive Heart Failure</i> , 2006, 12, 99-102.	2.0	2
346	Residual high-grade angina after enhanced external counterpulsation therapy. <i>Cardiovascular Revascularization Medicine</i> , 2007, 8, 161-165.	0.3	2
347	Audiocardiography in the cardiovascular evaluation of the morbidly obese. <i>Clinical Physiology and Functional Imaging</i> , 2010, 30, 369-374.	0.5	2
348	Chronic Anticoagulation in Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2483-2485.	1.2	2
349	Calling for Targeted Trials in Cardiorenal Syndromes. <i>American Journal of Kidney Diseases</i> , 2014, 64, 10-12.	2.1	2
350	Predicting Acute Kidney Injury in the Catheterization Laboratory. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1723-1724.	1.2	2
351	FP152 EFFECT OF BARDOXOLONE METHYL TREATMENT ON URINARY ALBUMIN IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE - POST-HOC ANALYSIS FROM BEAM AND BEACON. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i27-i27.	0.4	2
352	Analysis of electrocardiographic intervals before and after transcatheter aortic valve implantation to predict the need for permanent pacing. <i>Baylor University Medical Center Proceedings</i> , 2018, 31, 407-413.	0.2	2
353	Frequency of atrial arrhythmias after atrial flutter ablation and the effect of presenting rhythm on the day of ablation. <i>Baylor University Medical Center Proceedings</i> , 2018, 31, 280-283.	0.2	2
354	The Economic Impact of Mitral Regurgitation on Patients With Medically Managed Heart Failure. <i>American Journal of Cardiology</i> , 2019, 124, 1226-1231.	0.7	2
355	Comparison of reflex, resistance training, and core activities using change in blood pressure over time after spontaneous coronary artery dissection. <i>Baylor University Medical Center Proceedings</i> , 2019, 32, 113-115.	0.2	2
356	Cardiometabolic-Renal Disease in South Asians: Consensus Recommendations from the Cardio Renal Society of America. <i>CardioRenal Medicine</i> , 2019, 9, 240-251.	0.7	2
357	Key Updates in Cardio-Nephrology from 2018: Springboard to a Bright Future. <i>CardioRenal Medicine</i> , 2019, 9, 222-228.	0.7	2
358	Event dependence in the analysis of cardiovascular readmissions postpercutaneous coronary intervention. <i>Journal of Investigative Medicine</i> , 2019, 67, 943-949.	0.7	2
359	Heart-Kidney Cross-Talk. , 2019, , 664-670.e3.		2
360	Rate of major adverse renal or cardiac events with iohexol compared to other low osmolar contrast media during interventional cardiovascular procedures. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, E90-E97.	0.7	2

#	ARTICLE	IF	CITATIONS
361	Circulating plasma dipeptidyl dipeptidase 3 and the prognosis of cardiogenic shock. <i>European Journal of Heart Failure</i> , 2020, 22, 287-289.	2.9	2
362	Inpatient Mortality According to Level of Respiratory Support Received for Severe Acute Respiratory Syndrome Coronavirus 2 (Coronavirus Disease 2019) Infection: A Prospective Multicenter Study. , 2020, 2, e0220.		2
363	Healthcare utilization in clinically significant tricuspid regurgitation patients with and without heart failure. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 29-37.	0.6	2
364	Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in acute heart failure: invasive hemodynamic parameters and clinical outcomes. <i>Reviews in Cardiovascular Medicine</i> , 2021, 22, 199.	0.5	2
365	Nomenclature for Kidney Function from KDIGO: Shortcomings of Terminology Oversimplification. <i>CardioRenal Medicine</i> , 2021, 11, 1-4.	0.7	2
366	Impact of renin-angiotensin-aldosterone system inhibitor continuation on outcomes for patients with severe coronavirus disease 2019 manifestations. <i>Journal of Hypertension</i> , 2021, 39, 1725-1726.	0.3	2
367	Ranolazine: Focusing on angina pectoris. <i>Drugs of Today</i> , 2006, 42, 177.	0.7	2
368	Diagnostic and therapeutic utility of B-type natriuretic peptide in patients with renal insufficiency and decompensated heart failure. <i>Reviews in Cardiovascular Medicine</i> , 2003, 4 Suppl 7, S3-S12.	0.5	2
369	Integration of the clinical laboratory in cardiovascular medicine. <i>Reviews in Cardiovascular Medicine</i> , 2010, 11 Suppl 2, S1-2.	0.5	2
370	Advanced lipid testing: when, why, and in whom?. <i>Reviews in Cardiovascular Medicine</i> , 2014, 15, 310-7; quiz 318-9.	0.5	2
371	A Call to Action to Develop Integrated Curricula in Cardiorenal Medicine. <i>Reviews in Cardiovascular Medicine</i> , 2017, 18, 93-99.	0.5	2
372	Serum Cystatin C in the Estimation of Glomerular Filtration on Chronic Angiotensin-Converting Enzyme Inhibitor Therapy: An Illustrative Case Report. <i>Journal of Clinical Hypertension</i> , 2009, 11, 651-655.	1.0	1
373	Improving Detection of Cardiac Surgery-Associated Acute Kidney Injury—. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2763-2764.	1.2	1
374	Peter Andrew McCullough, MD, MPH: An Interview With the Editor. <i>American Journal of Cardiology</i> , 2014, 114, 1772-1785.	0.7	1
375	Cardiac Electromechanical Abnormalities in Hemodialysis Patients: Indicators of Cardiomyopathy and Future Risk?. <i>American Journal of Nephrology</i> , 2015, 42, 237-238.	1.4	1
376	Goal-Directed Heart Failure Care in Patients With Chronic Kidney Disease and End-Stage Renal Disease—. <i>JACC: Heart Failure</i> , 2016, 4, 662-663.	1.9	1
377	Decoding Acute Myocardial Infarction among Patients on Dialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1337-1339.	3.0	1
378	Urinary Metabolites in Patients Undergoing Coronary Catheterization Via the Radial Versus Femoral Artery Approach. <i>Baylor University Medical Center Proceedings</i> , 2017, 30, 404-409.	0.2	1

#	ARTICLE	IF	CITATIONS
379	Interpretation of Positive Troponin Results Among Patients with and Without Myocardial Infarction. Baylor University Medical Center Proceedings, 2017, 30, 11-15.	0.2	1
380	Acute kidney injury in cardiogenic shock: in search of early detection and clinical certainty. European Journal of Heart Failure, 2018, 20, 582-584.	2.9	1
381	Frequency of abnormal fractional flow reserve measurements among major coronary arteries. Cardiovascular Revascularization Medicine, 2019, 20, 143-146.	0.3	1
382	Clinical Context of Dyskalemias Across the Heart Failure Spectrum and Their Associated Adverse Outcomes. JACC: Heart Failure, 2019, 7, 533.	1.9	1
383	Cardiorenal Syndrome Type 1. , 2019, , 677-689.e2.		1
384	Limitations of transoesophageal echocardiogram in acute ischaemic stroke. Open Heart, 2020, 7, e001176.	0.9	1
385	Prevention Guidelines as Failed Minimal Standards of Care. American Journal of Cardiology, 2020, 125, 1441-1442.	0.7	1
386	The Reply. American Journal of Medicine, 2021, 134, e222-e223.	0.6	1
387	Ambulatory Worsening of Renal Function in Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2021, 77, 1222-1224.	1.2	1
388	CARDIOVASCULAR RISK MODIFICATION IN PARTICIPANTS WITH CORONARY DISEASE SCREENED BY THE KIDNEY EARLY EVALUATION PROGRAM. Internal Medicine Journal, 2010, , .	0.5	1
389	Early multidrug regimens in new potentially fatal medical problems. Reviews in Cardiovascular Medicine, 2020, 21, 507.	0.5	1
390	Angiotensin converting enzyme inhibitors and beta-blockers in African Americans with heart failure. Ethnicity and Disease, 2003, 13, 331-6.	1.0	1
391	Lipoproteins, inflammatory biomarkers, and cardiovascular imaging in the assessment of atherosclerotic disease activity. Reviews in Cardiovascular Medicine, 2009, 10, 51-8.	0.5	1
392	New vistas for the treatment of obesity: turning the tide against the leading cause of morbidity and cardiovascular mortality in the developed world. Reviews in Cardiovascular Medicine, 2014, 15 Suppl 2, S1-19; quiz S20-1.	0.5	1
393	Response. Chest, 2009, 135, 584-585.	0.4	0
394	Hazards of Contrast-Induced Acute Kidney Injury in Elderly Women. Women's Health, 2009, 5, 123-125.	0.7	0
395	Reply. Journal of the American College of Cardiology, 2017, 69, 1878-1879.	1.2	0
396	Editorial: Robertsonian Perspectives on Atherosclerosis: The Power of Direct Observation. American Journal of Cardiology, 2018, 121, 1441.	0.7	0

#	ARTICLE	IF	CITATIONS
397	FP804TWO-YEAR DURABILITY OF IMPROVEMENTS IN EGFR WITH BARDOXOLONE METHYL IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: THE LARIAT STUDY. Nephrology Dialysis Transplantation, 2018, 33, i634-i634.	0.4	0
398	Cardiorenal Syndrome: A Call to Action for a Pressing Medical Issue. Advances in Chronic Kidney Disease, 2018, 25, 379-381.	0.6	0
399	Common laboratory parameters as indicators of multi-organ dysfunction in acute heart failure. European Journal of Heart Failure, 2019, 21, 751-753.	2.9	0
400	Usefulness of coronary angiography in patients with left atrial myxoma. Baylor University Medical Center Proceedings, 2020, 33, 529-531.	0.2	0
401	Analysing risk in heart failure: a calcium check. European Journal of Heart Failure, 2020, 22, 1412-1414.	2.9	0
402	P0229APPLICATION OF A RISK MITIGATION STRATEGY TO PREVENT EXCESS CARDIOVASCULAR RISK IN PULMONARY HYPERTENSION: LARIAT STUDY. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
403	Regarding: "Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019". Annals of Medicine, 2021, 53, 286-286.	1.5	0
404	Screening for SARS-CoV-2 via PCR and serological testing in asymptomatic healthcare workers. Baylor University Medical Center Proceedings, 2021, 34, 437-441.	0.2	0
405	The Reply. American Journal of Medicine, 2021, 134, e298.	0.6	0
406	The Reply. American Journal of Medicine, 2021, 134, e346-e347.	0.6	0
407	The Reply. American Journal of Medicine, 2021, 134, e343-e344.	0.6	0
408	The Reply. American Journal of Medicine, 2021, 134, e440-e441.	0.6	0
409	The Reply. American Journal of Medicine, 2021, 134, e464.	0.6	0
410	Editorial. CardioRenal Medicine, 2021, , 1-2.	0.7	0
411	Adverse Events Following Coronary Angiography And Cardiac Surgery. , 2018, , .		0
412	The Promise of next generation sequencing micro RNA for the discovery of new targets in contrast induced acute kidney injury. Annals of Translational Medicine, 2019, 7, 424-424.	0.7	0
413	Mediators of the Effects of Canagliflozin on Heart Failure. JACC: Heart Failure, 2020, 8, 426.	1.9	0
414	A Call to Action to Develop Integrated Curricula in Cardiorenal Medicine. , 2020, , 449-461.		0

#	ARTICLE	IF	CITATIONS
415	A novel strategy to prevent contrast nephropathy: “Continuous hemodiafiltration” Catheterization and Cardiovascular Interventions, 2020, 96, 1182-1183.	0.7	0
416	Conventional risk factors and cardiac events--debunking an old myth about prevalence. Reviews in Cardiovascular Medicine, 2004, 5, 185-6.	0.5	0
417	Preface. Ximelagatran and oral direct thrombin inhibition. Reviews in Cardiovascular Medicine, 2004, 5 Suppl 5, S1.	0.5	0
418	Estimated glomerular filtration rate: why is it important?. Reviews in Cardiovascular Medicine, 2007, 8, 46-9.	0.5	0
419	Capturing the pathophysiology of acute coronary syndromes with circulating biomarkers. Reviews in Cardiovascular Medicine, 2010, 11 Suppl 2, S3-12.	0.5	0
420	Utilization of galectin-3 in case management across the spectrum of heart failure. Reviews in Cardiovascular Medicine, 2014, 15, 197-207.	0.5	0
421	Hyperuricemia and Cardiovascular Disease. Reviews in Cardiovascular Medicine, 2017, 18, 134-145.	0.5	0